MD Anderson and Xilis partner to expedite new cancer therapies development
Pharmaceutical Technology
FEBRUARY 16, 2023
It may offer opportunities for third-party collaborations to guide the new cell therapies and drugs development, if successful. The MOS platform can also expedite the disease model development, which offers new opportunities for further discovery research, drug development efforts, and translational science.
Let's personalize your content